Skip to content
Screener

Boston Scientific BSX Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Stryker logo
StrykerSYK
$0.100.0%
Haemonetics logo
HaemoneticsHAE
$0.010.0%
CONMED logo
CONMEDCNMD
Edwards Lifesciences logo
Edwards LifesciencesEW
ClearPoint Neuro logo
ClearPoint NeuroCLPT
Stereotaxis logo
StereotaxisSTXS

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$71.46B-53.2%
P/E19.5×-41.7×
P/S3.4×-4.9×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
(in millions, except share and per share data)As of / March 31, 2026As of / December 31, 2025
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of March 31, 2026 and December 31, 2025
Common stock, $0.01 par value - authorized 2,000,000,000 shares - 1,749,584,151 shares issued as of March 31, 2026 and 1,746,290,165 shares issued as of December 31, 20251717
Treasury stock, at cost - 263,289,848 shares as of March 31, 2026 and December 31, 2025(2,251)(2,251)
Additional paid-in capital21,58421,505
Retained earnings6,9125,571
Accumulated other comprehensive income (loss), net of tax(398)(610)

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's common stock, par value (in dollars per share)?
Boston Scientific (BSX) reported common stock, par value (in dollars per share) of $0.01 in Q1 2026.
How has Boston Scientific's common stock, par value (in dollars per share) changed year-over-year?
Boston Scientific's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0.01 to $0.01.
What is the long-term trend for Boston Scientific's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Boston Scientific's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.

Ask your AI about Boston Scientific's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude